FrancophonIA/ELRC3.0 huggingface dataset:
English: Because eluxadoline is not absorbed into the blood and distributed around the body, its effects are largely confined to the gut.
Croatian: Budući da se eluksadolin ne apsorbira u krv i ne širi kroz tijelo, njegovi učinci uglavnom su ograničeni na crijeva.
English: Truberzi must not be given to patients treated with a class of medicines known as potent OATP1B1 inhibitors (such as ciclosporin, a medicine that works on the immune system).
Croatian: Lijek Truberzi ne smije se davati bolesnicima koji su liječeni razredom lijekova koji su poznati kao potentni inhibitori proteina OATP1B1 (kao što je ciklosporin, lijek koji djeluje na imunosni sustav).
English: In patients who get troublesome side effects, the dose can be reduced to 75 mg each morning and evening.
Croatian: Bolesnicima s problematičnim nuspojavama doza se može smanjiti tako da uzimaju 75 mg svakog jutra i svaku večer.
English: Side effects were mainly limited to the digestive system and mostly mild.
Croatian: Nuspojave su uglavnom ograničene na probavni sustav i uglavnom su blage.
English: It is not intended to provide practical advice on how to use Truberzi.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Truberzi.
English: Truberzi eluxadoline
Croatian: Truberzi eluksadolin
English: What are the risks associated with Truberzi?
Croatian: Koji su rizici povezani s lijekom Truberzi?
English: Effectiveness was measured as an improvement of over 30% in abdominal pain combined with an absence of very loose stool.
Croatian: Mjerilo učinkovitosti bilo je poboljšanje simptoma abdominalne boli veće od 30 % u kombinaciji s izostankom vrlo mekane stolice
English: Why is Truberzi approved?
Croatian: Zašto je lijek Truberzi odobren?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Truberzi have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Truberzi nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that the benefits of Truberzi are modest but there is an unmet need for treatments of irritable bowel syndrome with diarrhoea.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji smatrao je da su koristi od lijeka Truberzi skromne, no da potrebe za terapijskim liječenjem sindroma iritabilnog crijeva s proljevom nisu zadovoljene.
English: The Committee therefore decided that Truberzi's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Stoga je Odbor odlučio da koristi od lijeka Truberzi nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: Eluxadoline, the active substance in Truberzi, is an opioid receptor agonist.
Croatian: Eluksadolin, djelatna tvar u lijeku Truberzi, je agonist opioidnih receptora.
English: Truberzi is a medicine that acts on the digestive system.
Croatian: Truberzi je lijek koji djeluje na probavni sustav.
English: Truberzi must not be given to patients with liver disorders, those at risk of pancreatitis (such as those who have had problems with their pancreas or who drink alcohol excessively), patients whose gall bladders have been removed or who have disorders affecting secretion of bile into the gut, and those who have had severe or long-term constipation or blocked bowel.
Croatian: Lijek Truberzi ne smije se davati bolesnicima s poremećajima rada jetre, bolesnicima s rizikom od pankreatitisa (primjerice bolesnicima koji su imali probleme s gušteračom ili koji prekomjerno konzumiraju alkohol), bolesnicima s uklonjenim žučnim mjehurom ili bolesnicima s poremećajima koji utječu na izlučivanje žuči u crijeva ili bolesnicima koji su imali problema s teškim ili dugotrajnim zatvorom ili blokiranim crijevima.
English: In both studies Truberzi was compared with placebo (a dummy treatment) over 26 weeks of treatment during which patients kept a daily record of their irritable bowel syndrome symptoms.
Croatian: U oba ispitivanja lijek Truberzi uspoređen je s placebom (prividno liječenje) u liječenju koje je trajalo više od 26 tjedana tijekom kojeg su bolesnici vodili dnevnu evidenciju o svojim simptomima sindroma iritabilnog crijeva.
English: This means that it attaches to opioid receptors and acts like the body's natural opioids to calm down waves of contractions along the digestive system.
Croatian: To znači da se veže na opioidne receptore i djeluje kao prirodni opioidi u tijelu koji umiruju kontrakcijske valove u probavnom sustavu.
English: Other information about Truberzi
Croatian: Ostale informacije o lijeku Truberzi:
English: The most common side effects with Truberzi (which may affect more than 5 in 100 people) are constipation, nausea (feeling sick) and abdominal pain.
Croatian: Najčešće su nuspojave lijeka Truberzi (koje se mogu javiti u više od 5 na 100 osoba) zatvor, mučnina (osjećaj slabosti) i abdominalna bol.
English: For more information about treatment with Truberzi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Truberzi pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: This causes food to remain in the gut for longer, increasing the absorption of fluids and so reducing diarrhoea.
Croatian: To omogućuje da se hrana dulje zadržava u crijevima čime se povećava apsorpcija tekućina i
English: In the second study symptoms improved in 33% (125 out of 382) of patients taking Truberzi 100 mg twice a day compared with 20% (77 out of 382) of patients taking placebo.
Croatian: U drugom ispitivanju do poboljšanja simptoma došlo je u 33 % (125 od 382) bolesnika koji su uzimali lijek Truberzi u dozi od 100 mg dvaput dnevno, u usporedbi s bolesnicima koji su primali placebo u kojih je do poboljšanja došlo u 20 % (77 od 382) bolesnika.
English: In the first study effectiveness was shown in 29% (125 out of 426) of patients taking Truberzi 100 mg twice a day compared with 19% (81 out of 427) in patients taking placebo.
Croatian: . U prvom ispitivanju, djelotvornost je zabilježena u 29 % (125 od 426) bolesnika koji su uzimali lijek Truberzi u dozi od 100 mg dvaput dnevno, u usporedbi s bolesnicima koji su primali placebo u kojih je učinkovitost zabilježena u 19 % (81 od 427) bolesnika.
English: For practical information about using Truberzi, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Truberzi bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: What benefits of Truberzi have been shown in studies?
Croatian: Koje su koristi lijeka Truberzi dokazane u ispitivanjima?
English: Truberzi was evaluated in two main studies involving over 2,400 patients with irritable bowel syndrome with diarrhoea.
Croatian: Lijek Truberzi ocjenjivan je u dvama glavnim ispitivanjima koja su provedena na više od 2400 bolesnika koji imaju sindrom iritabilnog crijeva uz proljev.
English: Truberzi can only be obtained with a prescription.
Croatian: Lijek Truberzi izdaje se samo na liječnički recept.
English: Irritable bowel syndrome is a long-term disorder of the gut with pain or discomfort in the abdomen (belly), bloating and altered bowel habit.
Croatian: Sindrom iritabilnog crijeva dugotrajan je poremećaj crijeva koji uzrokuje bol i neugodu u abdomenu (trbuhu) te nadutost i promijenjeni ritam pražnjenja crijeva.
English: It is used for the treatment of adults who have irritable bowel syndrome with diarrhoea.
Croatian: Primjenjuje se za liječenje odraslih osoba koje imaju sindrom iritabilnog crijeva s proljevom.
English: Serious side effects include pancreatitis (inflammation of the pancreas) and sphincter of Oddi spasm (a painful condition in which bile and digestive juices are blocked from flowing into the gut).
Croatian: Teške nuspojave uključuju pankreatitis (upalu gušterače) i grč Oddijevog mišića stezača žučnog kanala (bolno stanje pri kojem je onemogućen protok žučnih i probavnih sokova u crijeva).
English: How does Truberzi work?
Croatian: Kako djeluje lijek Truberzi?
English: How is Truberzi used?
Croatian: Kako se lijek Truberzi koristi?
English: For the full list of all side effects of Truberzi, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Truberzi potražite u uputi o lijeku.
English: Truberzi contains the active substance eluxadoline.
Croatian: Lijek Truberzi sadrži djelatnu tvar eluksadolin.
English: (Invented) name Strength Pharmaceutical form
Croatian: Farmaceutski oblik
English: Phone: +34 (0) 914856756
Croatian: Telefon: +34 (0) 914856756
English: • Risk management plan:
Croatian: • Plan upravljanja rizikom:
English: The onset of efficacy may be gradual.
Croatian: Djelotvornost se može pojaviti postupno.
English: Substantial improvement was shown in the next 48 hours and complete remission in the following two weeks.
Croatian: Znatno poboljšanje pokazalo se u sljedećih 48 sati, a potpuna remisija u sljedeća dva tjedna.
English: 28925 Madrid
Croatian: E-28925 Madrid
English: Efficacy data demonstrated an effect from 35 days after treatment.
Croatian: Podatci o djelotvornosti pokazali su učinak 35 dana nakon terapije.
English: The first report shall be submitted 6 months after Day 0, and subsequently at 6-month intervals, until otherwise agreed by the CVMP.
Croatian: Prvo izvješće mora se dostaviti šest mjeseci poslije dana 0, a nakon toga u šestomjesečnim intervalima, osim ako se s CVMP-om ne dogovori drugačije.
English: EXPIRY DATE EXP: {day/month/year}
Croatian: ROK VALJANOSTI EXP: {dan/mjesec/godina}
English: Use a 20G needle.
Croatian: Upotrijebite iglu promjera 20G.
English: The safety of the veterinary medicinal product has only been investigated in horses at least two years old.
Croatian: Neškodljivost veterinarsko-medicinskog proizvoda ispitivana je samo u konja u dobi od najmanje dvije godine.
English: Pharmacotherapeutic group: Not yet assigned ATCvet code: Not yet assigned
Croatian: FARMAKOLOŠKA SVOJSTVA Farmakoterapijska skupina: još nije dodijeljena Kod ATCvet: još nije dodijeljen
English: Shelf life of the veterinary medicinal product as packaged for sale: 14 days.
Croatian: Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju: 14 dana.
English: Swirl gently before use in order to ensure the contents are well mixed.
Croatian: Prije primjene lagano protresite da bi se sadržaj dobro izmiješao.
English: Ask your veterinary surgeon how to dispose of medicines no longer required.
Croatian: Upitajte svojeg veterinara kako odlagati veterinarsko-medicinske proizvode koji vam više nisu potrebni.
English: The starting date of the reporting scheme (Day 0) shall be the date of first release of a batch that has been tested with the updated and validated potency assay.
Croatian: Početak izvještavanja (dan 0) bit će datum prvog puštanja serije u promet koja je bila testirana ažuriranim i validiranim testom jačine.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 1 ml
Croatian: 3. SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJU DOZA 1 ml
English: Shelf life after first opening the immediate packaging: Use immediately.
Croatian: Rok valjanosti poslije prvog otvaranja unutarnjeg pakiranja: upotrijebiti odmah.
English: Correct placement of the needle is crucial to avoid accidental injection into blood vessels and an associated risk of thrombosis.
Croatian: Pravilno umetanje igle nužno je za izbjegavanje slučajnog injektiranja u krvne žile i povezanog rizika od tromboze.
English: The marketing authorisation holder shall perform the required pharmacovigilance activities and interventions as detailed in the agreed risk management plan and any agreed subsequent updates of the risk management plan.
Croatian: Nositelj odobrenja za stavljanje u promet dužan je provoditi dodatne farmakovigilancijske aktivnosti i intervencije, detaljno objašnjene u dogovorenom planu upravljanja rizikom te svim sljedećim dogovorenim ažuriranim verzijama plana upravljanja rizikom.
English: Pregnancy and lactation:
Croatian: Graviditet i laktacija::
English: MARKETING AUTHORISATION NUMBER(S) EU/2/18/226/001
Croatian: 16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/18/226/001
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml dose contains:
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Jedna doza od 1 ml sadrži:
English: Complete remission was observed within 3 days, without any symptomatic treatment.
Croatian: Potpuna remisija opažena je unutar 3 dana, bez ikakvog simptomatskog liječenja.
English: Interaction with other medicinal products and other forms of interactions
Croatian: Interakcije s drugim medicinskim proizvodima i drugi oblici interakcija
English: If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Croatian: Ako zamijetite bilo koju nuspojavu, čak i one koje nisu navedene u ovoj uputi o VMP-u, ili smatrate da veterinarsko-medicinski proizvod ne djeluje, obavijestite o tome veterinara.
English: Mesenchymal stem cells have immunomodulatory and anti-inflammatory properties that may be attributed to their paracrine activity, -e.g. prostaglandin (PGE2) secretion, and can possess tissue regenerative properties.
Croatian: Mezenhimske matične stanice imaju imunomodulacijska i protuupalna svojstva koja se mogu pripisati njihovoj parakrinoj aktivnosti, npr. lučenju prostaglandina (PGE2), i mogu imati sposobnost regeneracije tkiva.
English: In 5/6 horses, the adverse reactions were mild and resolved spontaneously within 28 days.
Croatian: U 5 od 6 konja nuspojave su bile blage i povukle su se spontano u roku od 28 dana.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Croatian: Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na internetskim stranicama Europske agencije za lijekove (http://www.ema.europa.eu/).
English: The veterinary product must be administered intraarticularly, only by a veterinary surgeon, taking special precautions to ensure the sterility of the injection process.
Croatian: Veterinarsko-medicinski proizvod mora se primijeniti intraartikularno, a smije ga davati samo veterinar uz posebne mjere opreza kojima se jamči sterilnost postupka injiciranja.
English: Complete remission was observed over the following two weeks without any symptomatic treatment.
Croatian: Potpuna remisija opažena je tijekom sljedeća dva tjedna bez ikakvog simptomatskog liječenja.
English: In order to further support the link between PGE2 production and a clinically-relevant therapeutic effect, the marketing authorisation holder shall conduct and submit an updated and validated potency assay (a product specific in vitro model) to the CVMP/EMA for evaluation before batch release and placing the product on the market.
Croatian: Kako bi se dodatno potkrijepila povezanost između proizvodnje PGE2 i klinički važnog terapijskog učinka, nositelj odobrenja za stavljanje u promet mora provesti i dostaviti CVMP-u/EMA-i ažuriran i validiran test jačine (in vitro model specifičan za VMP) radi procjene prije puštanja serije VMP-a u promet i njegova stavljanja na tržište.
English: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Croatian: U slučaju nehotičnog samoinjiciranja, odmah potražite savjet liječnika i pokažite mu uputu o VMP-u ili etiketu.
English: BATCH NUMBER Lot: {number}
Croatian: 6. BROJ SERIJE Lot: {broj}
English: Pack size: Cardboard box with 1 vial containing 1 ml.
Croatian: Veličina pakiranja: kartonska kutija s 1 bočicom koja sadržava 1 ml.
English: HEPES N-(2-hydroxyethyl) piperazine-N´-(2-ethanesulfonic acid) Sodium hydroxide
Croatian: HEPES N-(2-hidroksietil) piperazin-N´-(2-etansulfonska kiselina) natrijev hidroksid
English: The potential of EUC-MSCs to secrete PGE2 with and without stimulation by synovial fluid has been demonstrated in studies in vitro.
Croatian: Potencijal stanica EUC-MSC u pogledu lučenja PGE2 uz stimulaciju sinovijalnom tekućinom ili bez te stimulacije dokazan je u in vitro ispitivanjima.
English: Administrative office and manufacturing site: EquiCord-YMAS
Croatian: Uprava i mjesto proizvodnje: EquiCord-YMAS
English: The veterinary medicinal product was demonstrated to be efficacious in horses affected by osteoarthritis in the metacarpo-phalangeal joint, distal interphalangeal joint, and tarsometatarsal/ distal intertarsal joint.
Croatian: Veterinarsko-medicinski proizvod pokazao se djelotvornim u konja s osteoartritisom u metakarpofalangealnom zglobu, distalnom interfalangealnom zglobu i tarzometatarzalnom / distalnom intertarzalnom zglobu.
English: Incompatibilities:
Croatian: Glavne nekompatibilnosti:
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with any other veterinary medicinal products.
Croatian: U nedostatku ispitivanja kompatibilnosti, ovaj veterinarsko-medicinski proizvod ne smije se miješati ni s jednim drugim veterinarsko-medicinskim proizvodom.
English: Intraarticular placement should be confirmed by the appearance of synovial fluid in the hub of the needle.
Croatian: Intraartikularno umetnutu iglu treba potvrditi pojava sinovijalne tekućine u nastavku igle.
English: 4.6 Adverse reactions (frequency and seriousness)
Croatian: 4.6 Nuspojave (učestalost i ozbiljnost) Vrlo često:
English: A second administration of the product at the recommended dose to healthy young horses in the same joint, 28 days after the first administration at the recommended dose, led to an increase in frequency and severity of inflammation related to the treated joint (8/8 horses) and to an increase in the severity of the lameness observed (3/8 horses; up to grade 4/5 according to the American Association of Equine Practitioners lameness scale (AAEP)) compared to the first treatment.
Croatian: Druga primjena VMP-a u preporučenoj dozi zdravim mladim konjima u isti zglob, 28 dana poslije prve primjene u preporučenoj dozi, dovela je do veće učestalosti i težine upale u liječenom zglobu (8/8 konja) i do izraženijeg opaženog hramanja (3/8 konja; do 4./5. stupnja prema ljestvici hromosti američkog udruženja American Association of Equine Practitioners (AAEP)) u usporedbi s prvom terapijom.
English: In one case, symptomatic treatment (NSAID) was required.
Croatian: U jednom slučaju bilo je potrebno simptomatsko liječenje (NSAID).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL
Croatian: OSNOVNI PODATCI KOJI SE MORAJU NALAZITI NA MALIM UNUTARNJIM PAKIRANJIMA
English: In order to collect further field data, related to both safety and efficacy, from batches that have been released by use of the updated potency assay, the marketing authorisation holder shall conduct and submit the results of a surveillance study.
Croatian: Kako bi se prikupili dodatni podatci s terena u pogledu neškodljivosti i djelotvornosti serija koje su puštene u promet na temelju ažuriranog testa jačine, nositelj odobrenja za stavljanje u promet mora provesti i dostaviti rezultate nadzornog ispitivanja.
English: Adverse reactions in the other horses resolved spontaneously within a maximum of 21 days; lameness lasted for up to three days.
Croatian: Nuspojave kod drugih konja povukle su se spontano unutar najviše 21 dana; hromost je trajala do tri dana.
English: SPECIAL STORAGE CONDITIONS Store and transport refrigerated.
Croatian: 11. POSEBNE MJERE ČUVANJA Čuvati i prevoziti na hladnom.
English: Industrial Ventorro del Cano
Croatian: Industrial Ventorro del Cano Alcorcón
English: No efficacy data are available regarding the treatment of other joints.
Croatian: Nema podataka o djelotvornosti u pogledu liječenja drugih zglobova.
English: THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE
Croatian: 13. RIJEČI „SAMO ZA PRIMJENU NA ŽIVOTINJAMA” I UVJETI ILI OGRANIČENJA U
English: No efficacy data are available regarding the treatment in more than one arthritic joint at the same time.
Croatian: Nema podataka o djelotvornosti u pogledu liječenja više artritičnih zglobova istodobno.
English: METHOD AND ROUTE(S) OF ADMINISTRATION Swirl gently before use.
Croatian: NAČIN I PUT(EVI) PRIMJENE Prije primjene lagano protresite.
English: The product must be handled and injected following sterile techniques and in a clean environment.
Croatian: Proizvodom se mora rukovati te ga primijeniti prema pravilima sterilnih tehnika u čistom okruženju.
English: One horse required symptomatic treatment (NSAID) and its lameness resolved by day 14.
Croatian: Jednom konju bilo je potrebno simptomatsko liječenje (NSAID) i hromost mu se povukla do 14. dana.
English: An increase in mild lameness was observed 24 hours after HorStem administration.
Croatian: Blago povećanje hromosti opaženo je 24 sata poslije primjene HorStema.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the vial label.
Croatian: Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na naljepnici bočice.
English: Cloudy colourless suspension.
Croatian: Mutna bezbojna suspenzija.
English: Cyclic olefin vial closed with a bromobutyl rubber stopper and a flip off aluminium cap.
Croatian: Bočica od cikličkih olefinskih polimera zatvorena čepom od bromobutilne gume i aluminijskim poklopcem.
English: SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children.
Croatian: 11. POSEBNE MJERE OPREZA PRI ČUVANJU Čuvati izvan pogleda i dosega djece.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/18/226/001 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/06/2019
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/18/226/001 DATUM PRVOG ODOBRENJA / OBNOVE ODOBRENJA
English: Acute synovitis with an acute onset of severe lameness, joint effusion and pain on palpation was reported 24 hours after administration of the veterinary medicinal product.
Croatian: Akutni sinovitis s akutnim nastupom teške hromosti, efuzija zgloba i bol pri palpaciji zabilježeni su 24 sata poslije primjene veterinarsko-medicinskog proizvoda.
English: Do not administer simultaneously with any other intraarticular veterinary medicinal product.
Croatian: Ne primjenjivati istodobno s drugim veterinarsko-medicinskim proizvodima za intraartikularnu primjenu.
English: Intraarticular administration of a 2x dose (30x106/2ml) of HorStem to 4 years old and older healthy horses led to lameness in 5/6 animals and to signs of inflammation in all animals.
Croatian: Intraartikularna primjena 2x doze (30 x 106/2 ml) HorStema na zdravim konjima u dobi od 4 i više godina dovela je do pojave hromosti u 5 od 6 životinja te do znakova upale u svih životinja.
English: 5.2 Pharmacokinetic particulars
Croatian: 5.2 Farmakokinetički podatci
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Croatian: NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE SERIJE U PROMET, AKO SE RAZLIKUJU
English: Reduction of lameness associated with mild to moderate degenerative joint disease (osteoarthritis) in horses.
Croatian: Smanjenje hromosti povezane s blagom do umjerenom degenerativnom bolešću zglobova (osteoartritis) u konja.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT HorStem suspension for injection for horses
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA HorStem suspenzija za injekciju za konje